190 related articles for article (PubMed ID: 36913701)
1. Increased co-expression of TIM-3 with TIGIT or 2B4 on CD8+ T cells is associated with poor prognosis in locally advanced nasopharyngeal carcinoma.
Xie X; Feng Y; Fan P; Dong D; Yao X; Peng Y; Wang R
Biomol Biomed; 2023 Jul; 23(4):584-595. PubMed ID: 36913701
[TBL] [Abstract][Full Text] [Related]
2. High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer.
Mollavelioglu B; Cetin Aktas E; Cabioglu N; Abbasov A; Onder S; Emiroglu S; Tükenmez M; Muslumanoglu M; Igci A; Deniz G; Ozmen V
World J Surg Oncol; 2022 Oct; 20(1):349. PubMed ID: 36271406
[TBL] [Abstract][Full Text] [Related]
3. TIGIT
Yu L; Liu X; Wang X; Yan F; Wang P; Jiang Y; Du J; Yang Z
Oncoimmunology; 2021; 10(1):1942673. PubMed ID: 34249476
[TBL] [Abstract][Full Text] [Related]
4. Co-expression of PD-1 with TIGIT or PD-1 with TIM-3 on tumor-infiltrating CD8
Meyiah A; Mahmoodi Chalbatani G; Al-Mterin MA; Malekraeisi MA; Murshed K; Elkord E
Int Immunopharmacol; 2023 Jun; 119():110207. PubMed ID: 37099940
[TBL] [Abstract][Full Text] [Related]
5. A Comprehensive Analysis of Key Immune Checkpoint Receptors on Tumor-Infiltrating T Cells From Multiple Types of Cancer.
Li X; Wang R; Fan P; Yao X; Qin L; Peng Y; Ma M; Asley N; Chang X; Feng Y; Hu Y; Zhang Y; Li C; Fanning G; Jones S; Verrill C; Maldonado-Perez D; Sopp P; Waugh C; Taylor S; Mcgowan S; Cerundolo V; Conlon C; McMichael A; Lu S; Wang X; Li N; Dong T
Front Oncol; 2019; 9():1066. PubMed ID: 31709176
[No Abstract] [Full Text] [Related]
6. TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8
Ge Z; Zhou G; Campos Carrascosa L; Gausvik E; Boor PPC; Noordam L; Doukas M; Polak WG; Terkivatan T; Pan Q; Takkenberg RB; Verheij J; Erdmann JI; IJzermans JNM; Peppelenbosch MP; Kraan J; Kwekkeboom J; Sprengers D
Cell Mol Gastroenterol Hepatol; 2021; 12(2):443-464. PubMed ID: 33781741
[TBL] [Abstract][Full Text] [Related]
7. PD-1
Liu X; Li M; Wang X; Dang Z; Jiang Y; Wang X; Kong Y; Yang Z
Cancer Immunol Immunother; 2019 Dec; 68(12):2041-2054. PubMed ID: 31720814
[TBL] [Abstract][Full Text] [Related]
8. Increased Expression and Modulated Regulatory Activity of Coinhibitory Receptors PD-1, TIGIT, and TIM-3 in Lymphocytes From Patients With Systemic Sclerosis.
Fleury M; Belkina AC; Proctor EA; Zammitti C; Simms RW; Lauffenburger DA; Snyder-Cappione JE; Lafyatis R; Dooms H
Arthritis Rheumatol; 2018 Apr; 70(4):566-577. PubMed ID: 29245183
[TBL] [Abstract][Full Text] [Related]
9. Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study.
Shi X; Li CW; Tan LC; Wen SS; Liao T; Zhang Y; Chen TZ; Ma B; Yu PC; Lu ZW; Qu N; Wang Y; Shi RL; Wang YL; Ji QH; Wei WJ
J Clin Endocrinol Metab; 2021 Jan; 106(1):120-132. PubMed ID: 33000173
[TBL] [Abstract][Full Text] [Related]
10. Tim-3 signaling blockade with α-lactose induces compensatory TIGIT expression in Plasmodium berghei ANKA-infected mice.
Zhang Y; Jiang N; Zhang T; Chen R; Feng Y; Sang X; Yang N; Chen Q
Parasit Vectors; 2019 Nov; 12(1):534. PubMed ID: 31711531
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Protein Expression Defines the Prognosis of Advanced Thyroid Carcinoma.
Luo Y; Yang YC; Shen CK; Ma B; Xu WB; Wang QF; Zhang Y; Liao T; Wei WJ; Wang Y
Front Endocrinol (Lausanne); 2022; 13():859013. PubMed ID: 35574031
[TBL] [Abstract][Full Text] [Related]
12. TIGIT promotes CD8
Liang R; Zhu X; Lan T; Ding D; Zheng Z; Chen T; Huang Y; Liu J; Yang X; Shao J; Wei H; Wei B
Cancer Immunol Immunother; 2021 Oct; 70(10):2781-2793. PubMed ID: 33634371
[TBL] [Abstract][Full Text] [Related]
13. Differential Expression of Novel Immune Checkpoint Receptors on Tumor Infiltrating Lymphocytes in Patients with Locally Advanced Breast Cancer after Neoadjuvant Chemotherapy.
Abbasov A; Aktas Cetin E; Cabioglu N; Mollavelioglu B; Onder S; Emiroglu S; Tükenmez M; Muslumanoglu M; Igci A; Deniz G; Ozmen VO
Neoplasma; 2021 Sep; 68(5):1079-1090. PubMed ID: 34097428
[TBL] [Abstract][Full Text] [Related]
14. Implications of PD-1, Tim-3, and TIGIT Expression for Cancer Immunity and Pancreatic Cancer Prognosis.
Nakayama C; Tanoue K; Idichi T; Shimomura H; Kita Y; Hozaka Y; Shinden Y; Matsushita D; Nakajo A; Arigami T; Mataki Y; Kurahara H; Ohtsuka T
Anticancer Res; 2022 Jul; 42(7):3373-3380. PubMed ID: 35790289
[TBL] [Abstract][Full Text] [Related]
15. TIGIT expression is upregulated in T cells and causes T cell dysfunction independent of PD-1 and Tim-3 in adult B lineage acute lymphoblastic leukemia.
Zhang X; Zhang H; Chen L; Feng Z; Gao L; Li Q
Cell Immunol; 2019 Oct; 344():103958. PubMed ID: 31376919
[TBL] [Abstract][Full Text] [Related]
16. Presence of Tim3
Klapholz M; Drage MG; Srivastava A; Anderson AC
J Pathol; 2022 Jun; 257(2):186-197. PubMed ID: 35119692
[TBL] [Abstract][Full Text] [Related]
17. CD28/PD1 co-expression: dual impact on CD8
Palermo B; Franzese O; Frisullo G; D'Ambrosio L; Panetta M; Campo G; D'Andrea D; Sperduti I; De Nicola F; Goeman F; Gallina F; Visca P; Facciolo F; Nisticò P
J Exp Clin Cancer Res; 2023 Oct; 42(1):287. PubMed ID: 37898752
[TBL] [Abstract][Full Text] [Related]
18. Increased coexpression of PD-L1 and TIM3/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma.
Wang P; Chen Y; Long Q; Li Q; Tian J; Liu T; Wu Y; Ding Z
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34625514
[TBL] [Abstract][Full Text] [Related]
19. Increased Expression of Multiple Co-Inhibitory Molecules on Malaria-Induced CD8
Brandi J; Riehn M; Hadjilaou A; Jacobs T
Front Immunol; 2022; 13():878320. PubMed ID: 35874786
[TBL] [Abstract][Full Text] [Related]
20. Human regulatory memory B cells defined by expression of TIM-1 and TIGIT are dysfunctional in multiple sclerosis.
Varghese JF; Kaskow BJ; von Glehn F; Case J; Li Z; Julé AM; Berdan E; Ho Sui SJ; Hu Y; Krishnan R; Chitnis T; Kuchroo VK; Weiner HL; Baecher-Allan CM
Front Immunol; 2024; 15():1360219. PubMed ID: 38745667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]